zynerba
pharmaceuticals
presents
data
supporting
methylation
status
correlate
fragile
x
syndrome
severity
virtual
joint
international
child
neurology
congress
icnc
devon
globe
newswire
zynerba
pharmaceuticals
nasdaq
zyne
leader
innovative
transdermal
cannabinoid
therapies
rare
neuropsychiatric
disorders
presenting
poster
describing
data
clinical
study
cannabidiol
cbd
children
adolescents
fragile
x
trial
describing
role
methylation
status
children
adolescents
fragile
x
syndrome
fxs
correlate
disease
severity
prognostic
biomarker
data
presented
virtual
joint
international
child
neurology
congress
icnc
annual
child
neurology
society
cns
meeting
data
also
presented
oral
presentation
research
pipeline
new
findings
diagnostic
therapeutics
session
virtual
american
academy
child
adolescent
psychiatry
aacap
annual
meeting
friday
october
copy
poster
entitled
cannabidiol
transdermal
gel
children
adolescents
fragile
x
syndrome
role
methylation
status
correlate
disease
severity
prognostic
biomarker
available
zynerba
corporate
website
http
publications
excited
provide
update
potential
role
methylation
status
gene
predictive
biomarker
preferential
response
treatment
behavioral
symptoms
fxs
said
zynerba
chief
medical
officer
joseph
palumbo
md
fapa
macpsych
new
data
demonstrate
patients
diagnosed
fxs
fully
methylated
gene
significantly
patients
received
zygel
achieved
clinically
meaningful
improvement
behavioral
symptoms
compared
patients
received
randomized
multinational
pivotal
study
evaluate
efficacy
safety
zygel
children
adolescents
aged
years
although
full
analysis
set
achieve
statistical
significance
endpoints
building
current
scientific
evidence
ad
hoc
analysis
patients
least
methylation
full
methylation
fmet
impacted
gene
representing
overall
study
population
performed
results
including
achievement
statistical
significance
primary
endpoint
improvement
weeks
treatment
social
avoidance
subscale
fxs
compared
placebo
suggest
zygel
may
benefit
patients
full
methylation
gene
zynerba
utilized
psychometric
analyses
determine
constitutes
clinically
meaningful
change
baseline
measured
subscales
fxs
new
results
described
today
include
results
analyses
support
definition
clinically
meaningful
treatment
response
weeks
treatment
improvement
three
points
greater
social
avoidance
subscale
nine
points
greater
irritability
subscale
five
points
greater
socially
unresponsive
lethargic
subscale
company
determined
fmet
patients
receiving
zygel
achieved
clinically
meaningful
change
socially
avoidant
behavior
compared
patients
receiving
placebo
statistically
significant
patients
receiving
zygel
achieved
clinically
meaningful
change
irritability
compared
patients
receiving
placebo
statistically
significant
figure
greater
percentages
participants
achieved
meaningful
change
fxs
social
avoidance
irritability
vs
placebo
https
newsroom
attachmentng
authors
poster
concluded
knowledge
largest
controlled
study
ever
performed
fxs
results
may
represent
important
step
forward
prediction
response
fxs
neuroscience
zygel
well
tolerated
safety
profile
consistent
previously
reported
clinical
trials
fmet
group
zygel
superior
placebo
multiple
analyses
including
statistically
significant
mean
change
social
avoidance
vs
placebo
proportion
patients
attaining
threshold
clinically
meaningful
change
social
avoidance
irritability
caregiver
reported
improvements
including
statistically
significant
improvements
social
avoidance
isolation
social
interaction
irritable
disruptive
behaviors
zynerba
meeting
fda
fourth
quarter
discuss
data
zynerba
pharmaceuticals
zynerba
pharmaceuticals
leader
transdermal
cannabinoid
therapies
rare
neuropsychiatric
disorders
committed
improving
lives
patients
families
living
severe
chronic
health
conditions
including
fragile
x
syndrome
autism
spectrum
disorder
deletion
syndrome
heterogeneous
group
rare
epilepsies
known
developmental
epileptic
encephalopathies
learn
follow
us
twitter
zynerbapharma
cautionary
note
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
may
cases
use
terms
predicts
believes
potential
proposed
continue
estimates
anticipates
expects
plans
intends
may
could
might
words
convey
uncertainty
future
events
outcomes
identify
statements
statements
subject
numerous
important
factors
risks
uncertainties
may
cause
actual
events
results
differ
materially
company
current
expectations
management
expectations
therefore
statements
press
release
could
also
affected
risks
uncertainties
relating
number
factors
including
following
company
cash
cash
equivalents
may
sufficient
support
operating
plan
long
anticipated
company
ability
obtain
additional
funding
support
clinical
development
programs
results
cost
timing
company
clinical
development
programs
including
delays
clinical
trials
relating
enrollment
site
initiation
clinical
results
company
product
candidates
may
replicated
continue
occur
additional
trials
may
otherwise
support
development
specified
indication
actions
advice
food
drug
administration
foreign
regulatory
agencies
may
affect
design
initiation
timing
continuation
progress
clinical
trials
result
need
additional
clinical
trials
company
ability
obtain
maintain
regulatory
approval
product
candidates
labeling
approval
company
reliance
third
parties
assist
conducting
clinical
trials
product
candidates
delays
interruptions
failures
manufacture
supply
company
product
candidates
company
ability
commercialize
product
candidates
size
growth
potential
markets
company
product
candidates
company
ability
service
markets
company
ability
develop
sales
marketing
capabilities
whether
alone
potential
future
collaborators
rate
degree
market
acceptance
company
product
candidates
company
expectations
regarding
ability
obtain
adequately
maintain
sufficient
intellectual
property
protection
product
candidates
timing
outcome
current
future
legal
proceedings
extent
health
epidemics
outbreaks
communicable
diseases
including
could
disrupt
operations
adversely
affect
business
financial
conditions
list
exhaustive
risks
described
company
periodic
reports
including
annual
report
form
quarterly
reports
form
current
reports
form
filed
furnished
securities
exchange
commission
available
statements
company
makes
press
release
speak
date
press
release
company
assumes
obligation
update
statements
whether
result
new
information
future
events
otherwise
date
press
release
zynerba
contact
roberts
vp
investor
relations
corporate
communications
robertsw
media
contact
molly
devlin
evoke
kyne
